Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study aims to prevent deadly complications after liver transplant

NCT ID NCT06169592

Disease control Sponsor: Republican Specialized Scientific and Practical Medical Center of Surgery Named After V. Vakhidov Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows 30 adults with end-stage liver cirrhosis who receive a living-donor liver transplant. Researchers track bleeding and clotting complications to identify risk factors and improve prevention strategies. The goal is to make liver transplants safer in the early recovery period.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
liver transplantation (right lobe from living donor)
What this could lead to
If successful, this could help doctors better predict and prevent dangerous bleeding or clotting after a liver transplant, improving patient survival.
What could go wrong
This is a small, early-stage study with only 30 participants, so results may not apply to all patients. It focuses on identifying risks, not testing a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2022

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with end stage liver cirrhosis who underwent living related liver transplantation.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age over 18 years and up to 70 years; * Signed informed consent for inclusion to the study; * End stage liver cirrhosis. Exclusion Criteria: * Pregnancy; * Extrahepatic factors influencing systemic hemostasis; * Concomitant hematological diseases affecting the hemostatic system; * Severe concomitant disorders.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for End stage liver cirrhosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic liver failure cirrhosis of liver

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Liver cirrhosis Liver transplant; complications

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Republican specialized scientific and practical medical center of surgery named after academician V.Vakhidov

    RECRUITING

    Tashkent, 100115, Uzbekistan

More trials for these conditions

Other studies related to the condition(s) this trial covers.